PRNewsWire
08 Jun 2026, 16:51 UTC · 2h ago
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
PRNewsWire
08 Jun 2026, 16:51 UTC · 2h ago
Story key points
3 claims · impact-rated
The FDA issued a Complete Response Letter (CRL) rejecting Grace Therapeutics' New Drug Application for GTx-104. — A CRL is a major regulatory setback that halts a drug's path to market, directly impacting the company's primary value driver.
-0.90The FDA cited deficiencies in product packaging leachables, toxicology risk assessments, and contract manufacturing organization operations. — Specific manufacturing and clinical deficiencies indicate that the path to approval may require costly and time-consuming remediation.
-0.60The Schall Law Firm has launched a fraud investigation into Grace Therapeutics for potential violations of securities laws. — Legal investigations and potential class-action lawsuits create additional financial liability and governance risk.
-0.40Ticker attribution
Continue reading
6 related stories
Top 3 movers · tap to explore
Model heads
The company is facing a fraud investigation following an FDA Complete Response Letter and a nearly 46% drop in share price.
The company is the subject of a fraud investigation by the Schall Law Firm.
The company is the subject of a fraud investigation by the Schall Law Firm.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
3 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
PRNewsWire
11h ago
